Lamal tablets 25 mg. №30

$25.00

Manufacturer: Macedonia

Epilepsy: adults and adolescents from the age of 12: monotherapy and additional therapy for epilepsy, in particular partial and generalized seizures, including tonic-clonic attacks, as well as attacks associated with Lennox-Gastaut syndrome; children from 2 to 12 years of age: additional therapy for epilepsy, in particular partial and generalized seizures, including tonic-clonic attacks, as well as attacks associated with Lennox-Gastaut syndrome.

Category:

Description

Lamal 25 mg Storage
active substance: lamotrigine;

1 tablet contains lamotrigine 25 mg or 50 mg, or 100 mg, or 200 mg;

Excipients: low-substituted hydroxypropylcellulose, calcium carbonate, sodium starch glycolate (type A), colloidal anhydrous silica, aluminum-magnesium silicate, magnesium stearate, sodium saccharin, povidone, microcrystalline cellulose, flavoring additives E 1518), triethyl citrate (E 1505), caramel ammonia sulfate (E 150D).

Lamal 25 mg Dosage form
Tablets.

Basic physical and chemical properties:

25 mg tablets: white round biconvex tablets;

tablets of 50 mg or 100 mg, or 200 mg: white round biconvex tablets with a line on one side.

Lamal 25 mg Pharmacotherapeutic group
Antiepileptic drugs. Other antiepileptic drugs. ATX code N03A X09.

Pharmacological properties

Pharmacodynamics

Lamotrigine is an anticonvulsant whose mechanism of action is to block potential-dependent sodium channels of the presynaptic membrane. This reduces the release of mediators into the synaptic cleft, primarily glutamate, an amino acid that plays an important role in the onset of an epileptic seizure.

Pharmacokinetics

After oral administration, the drug is rapidly and completely absorbed from the gastrointestinal tract. The maximum concentration in blood plasma Cmax is reached in 2-3 hours. The time to reach Cmax is slightly prolonged after eating, but the degree of absorption does not change.

Lamotrigine is metabolized in the liver by glucuring. The half-life significantly depends on concomitant drugs. Less than 10% of lamotrigine is excreted in the urine without being absorbed by the body. Almost 2% is excreted in the feces. The half-life of lamotrigine is on average 24-35 hours.

It passes into breast milk in concentrations that are 40-60% of that in blood plasma.

Indication
Epilepsy:

Adults and adolescents over 13 years of age: monotherapy and adjunctive therapy for epilepsy, including partial and generalized seizures, including tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome. Lamictal is prescribed as adjunctive therapy, but in Lennox-Gastaut syndrome it can be prescribed as an initial antiepileptic drug (PEP);
children 2 to 12 years of age: adjunctive therapy for epilepsy, including partial and generalized seizures, including tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome.
Monotherapy of typical small epileptic seizures.

Bipolar disorder in adults.

To prevent cases of emotional disturbances, mainly to prevent depressive episodes in patients with type I bipolar disorder.

Lamictal is not indicated for the immediate treatment of manic or depressive episodes.

Lamal 25 mg Contraindication
Hypersensitivity to lamotrigine or to any of the excipients.

Expiration date
3 years.

Storage conditions
Store at a temperature not exceeding 25 oC.

Keep out of reach of children.

Packaging
25 mg and 50 mg tablets: 10 tablets in a blister of aluminum foil and polyvinyl chloride film; 3 blisters (30 tablets) in a pack of cardboard.

Tablets of 100 mg and 200 mg: 15 tablets in a blister of aluminum foil and polyvinyl chloride film; 2 blisters (30 tablets) in a cardboard pack.

Vacation category
According to the recipe.